Showing 1681-1690 of 2152 results for "".
- Market Scope: Cornea Products Market to Grow an Estimated 6.1 Percent Through 2025https://modernod.com/news/market-scope-cornea-products-market-to-grow-an-estimated-6-1-percent-through-2025/2478618/Expanding use of products to treat many corneal diseases will increase the role of devices and surgery in the cornea treatment landscape, according to Market Scope. Over 1 billion people are affected by 50 corneal diseases that cause cornea impairment, including corneal ectasias, dystrophies, ker
- Report: Dry Eye Treatment Devices Market Size Worth $400.8 Million By 2027https://modernod.com/news/report-dry-eye-treatment-devices-market-size-worth-400-8-million-by-2027/2478591/The global dry eye treatment devices market size is estimated to reach US$400.8 million by 2027, expanding at a CAGR of 6.4%, according to a new report by Grand View Research, Inc. The increasing demand for targeted, noninvasive, faster, and patient compliant treatment methods to alleviate dry ey
- GenSight Biologics Reports Validation of Lumevoq Marketing Authorization Application (MAA) by European Medicines Agencyhttps://modernod.com/news/gensight-biologics-reports-validation-of-lumevoq-marketing-authorization-application-maa-by-european-medicines-agency/2478488/GenSight Biologics reported that the Lumevoq Marketing Authorization Application (MAA) passed the validation checks required for submissions to the European Medicines Agency (EMA), triggering the official start of the MAA review procedure. The application for use of Lumevoq gene therapy to treat
- Concerns Over Surgical Waste Are Clouding Future of Single-Use Device Markethttps://modernod.com/news/concerns-over-surgical-waste-are-clouding-future-of-single-use-device-market/2478423/The global single-use surgical device market has shown steady growth over several decades, reaching a peak of $3.4 billion in 2019, but growing concerns over the amount of waste created by disposable surgical devices have raised questions about future growth prospects, according to a Market Scope
- Optimo Medical Gets Support by Innosuisse to Enter the US Markethttps://modernod.com/news/optimo-medical-gets-support-by-innosuisse-to-enter-the-us-market/2478322/Optimo Medical announced that Optimeyes is ready to enter the US market after the FDA decided not to enforce any regulatory requirements, known as enforcement discretion. This important step forward opened the doors for Optimo Medical to receive the additional boost of a Swissnex bootcamp
- GenSight Biologics Submits EU Marketing Authorization Application for LHON Gene Therapy Lumevoqhttps://modernod.com/news/gensight-biologics-submits-eu-marketing-authorization-application-for-lhon-gene-therapy-lumevoq/2478287/GenSight Biologics announced that it has submitted the Marketing Authorization Application (MAA) for its lead product Lumevoq to the European Medicines Agency (EMA), seeking approval for the treatment of patients with vision loss due to Leber Hereditary Optic Neuropathy (LHON) caused by mutation
- Nicox Partners Zerviate in the Gulf and Arab Marketshttps://modernod.com/news/nicox-partners-zerviate-in-the-gulf-and-arab-markets/2478152/Nicox SA announced the signature of an exclusive license agreement with Itrom Pharmaceutical Group for the registration and commercialization of Zerviate (cetirizine ophthalmic solution), 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in Gulf and Arab markets. I
- Diagnostic Market Sees New Demand Due to Effects of COVID-19https://modernod.com/news/diagnostic-market-sees-new-demand-due-to-effects-of-covid-19/2478150/Increasing demand for telehealth and mobile applications due to the COVID-19 pandemic has led manufacturers to scramble to add functionality and accessibility to existing devices and protection apparatuses or create new devices, according to a Market Scope report. Regulatory bodies and re
- Novartis Withdraws Marketing Application of Dry Eye Drug Xiidra in Europehttps://modernod.com/news/novartis-pulls-eu-filing-seeking-approval-of-xiidra-for-dry-eye-disease/2477942/Novartis has decided to withdraw its marketing application seeking approval of dry eye drug Xiidra (lifitegrast) in Europe. The decision comes after the European Medicines Agency (EMA) said the drug’s benefits did not outweigh its risks. Novartis pulled the application on June 18 after the
- Market Scope: Premium IOL Volume Faces Challenges in Rebounding Post-COVIDhttps://modernod.com/news/market-scope-premium-iol-volume-faces-challenges-in-rebounding-post-covid/2477871/Results from Part 1 of Market Scope’s “COVID-19 US Practice Impact Survey” reveal that nearly 41 percent of surgeons expect a decrease in premium IOL conversion once COVID-19 subsides. These surgeons expect an average decrease of 34 percent, and most respondents believe that financial